Pexmetinib (ARRY-614)是一种有效的口服生物可利用双重抑制剂，适用于急性髓系白血病的研究，已进入一期临床试验阶段。
| 英文别名 (English Synonym) | Pexmetinib (ARRY-614) |
| 中文名称 (Chinese Name) | |
| 靶点 (Target) | p38 |
| 通路 (Pathway) | MAPK/ERK |
| CAS号 (CAS NO.) | 945614-12-0 |
| 分子式 (Formula) | C31H33FN6O3 |
| 分子量 (Molecular Weight) | 556.64 |
| 纯度 (Purity) | ≥98% |
| 溶解性 (Solubility) | 溶于DMSO |
-25~-15℃保存，有效期3年
[1] Bachegowda L, Morrone K, Winski SL, Mantzaris I, Bartenstein M, Ramachandra N, Giricz O, Sukrithan V, Nwankwo G, Shahnaz S, Bhagat T, Bhattacharyya S, Assal A, Shastri A, Gordon-Mitchell S, Pellagatti A, Boultwood J, Schinke C, Yu Y, Guha C, Rizzi J, Garrus J, Brown S, Wollenberg L, Hogeland G, Wright D, Munson M, Rodriguez M, Gross S, Chantry D, Zou Y, Platanias L, Burgess LE, Pradhan K, Steidl U, Verma A. Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia. Cancer Res. 2016 Aug 15;76(16):4841-4849. doi: 10.1158/0008-5472.CAN-15-3062. Epub 2016 Jun 10. PMID: 27287719; PMCID: PMC5398415.
